Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016 (2016), Article ID 4647685, 10 pages
http://dx.doi.org/10.1155/2016/4647685
Review Article

Urinary Markers of Tubular Injury in Early Diabetic Nephropathy

Department of Clinical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia

Received 22 February 2016; Accepted 26 April 2016

Academic Editor: Franca Anglani

Copyright © 2016 Temesgen Fiseha and Zemenu Tamir. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Ninomiya, V. Perkovic, B. E. de Galan et al., “Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes,” Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1813–1821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P.-H. Groop, M. C. Thomas, J. L. Moran et al., “The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes,” Diabetes, vol. 58, no. 7, pp. 1651–1658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Targher, G. Zoppini, M. Chonchol et al., “Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 4, pp. 294–301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Atkins and P. Zimmet, “Editorial: Diabetic kidney disease: act now or pay later,” Kidney International, vol. 77, no. 5, pp. 375–377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Walczak, M. Sodolska, I. Materek, A. Krysicka, and D. Moczulski, “Impaired renal function in type 2 diabetes patients in the absence of increased urine albumin excretion rate,” Diabetologia Doświadczalna i Kliniczna, vol. 8, no. 4, pp. 165–168, 2008. View at Google Scholar
  6. M. L. Caramori, P. Fioretto, and M. Mauer, “Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions,” Diabetes, vol. 52, no. 4, pp. 1036–1040, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Budhiraja, B. Thajudeen, and M. Popovtzer, “Absence of albuminuria in type 2 diabetics with classical diabetic nephropathy: clinical pathological study,” Journal of Biomedical Science and Engineering, vol. 6, no. 5, pp. 20–25, 2013. View at Publisher · View at Google Scholar
  8. J. Barratt and P. Topham, “Urine proteomics: the present and future of measuring urinary protein components in disease,” Canadian Medical Association Journal, vol. 177, no. 4, pp. 361–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. MacIsaac and G. Jerums, “Diabetic kidney disease with and without albuminuria,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 3, pp. 246–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Thomas, W. C. Burns, and M. E. Cooper, “Tubular changes in early diabetic nephropathy,” Advances in Chronic Kidney Disease, vol. 12, no. 2, pp. 177–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. W. Tang and K. N. Lai, “The pathogenic role of the renal proximal tubular cell in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3049–3056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Gibb, P. A. Tomlinson, N. R. Dalton, C. Turner, V. Shah, and T. M. Barratt, “Renal tubular proteinuria and microalbuminuria in diabetic patients,” Archives of Disease in Childhood, vol. 64, no. 1, pp. 129–134, 1989. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. W. Tang, J. C. K. Leung, and K. N. Lai, “Diabetic tubulopathy: an emerging entity,” Diabetes and the Kidney, vol. 170, pp. 124–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. L. Nauta, W. E. Boertien, S. J. L. Bakker et al., “Glomerular and tubular damage markers are elevated in patients with diabetes,” Diabetes Care, vol. 34, no. 4, pp. 975–981, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. V. Bonventre, “Can we target tubular damage to prevent renal function decline in diabetes?” Seminars in Nephrology, vol. 32, no. 5, pp. 452–562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. V. S. Vaidya, M. A. Niewczas, L. H. Ficociello et al., “Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase,” Kidney International, vol. 79, no. 4, pp. 464–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Lacquaniti, V. Donato, B. Pintaudi et al., “‘Normoalbuminuric’ diabetic nephropathy: tubular damage and NGAL,” Acta Diabetologica, vol. 50, no. 6, pp. 935–942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Abd El Dayem, A. E. El Bohy, and A. El Shehaby, “Value of the intrarenal arterial resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients,” Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 3, pp. 273–279, 2015. View at Publisher · View at Google Scholar
  19. J. A. de Carvalho, E. Tatsch, B. S. Hausen et al., “Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes,” Clinical Biochemistry, vol. 49, no. 3, pp. 232–236, 2016. View at Publisher · View at Google Scholar
  20. K. Mori and K. Nakao, “Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage,” Kidney International, vol. 71, no. 10, pp. 967–970, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Kim, S. H. Song, I. J. Kim et al., “Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 251–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Nielsen, K. J. Schjoedt, A. S. Astrup et al., “Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril,” Diabetic Medicine, vol. 27, no. 10, pp. 1144–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. H. Hafez, F. A. F. El-Mougy, S. H. Makar, and S. S. Abd El Shaheed, “Detection of an earlier tubulopathy in diabetic nephropathy among children with normoalbuminuria,” Iranian Journal of Kidney Diseases, vol. 9, no. 2, pp. 126–131, 2015. View at Google Scholar · View at Scopus
  24. Z. Yürük Yıldırım, A. Nayır, A. Yılmaz, A. Gedikbaşı, and R. Bundak, “Neutrophil gelatinase-associated lipocalin as an early sign of diabetic kidney injury in children,” Journal of Clinical Research in Pediatric Endocrinology, vol. 7, no. 4, pp. 274–279, 2015. View at Publisher · View at Google Scholar
  25. H. S. Assal, S. Tawfeek, E. A. Rasheed, D. El-Lebedy, and E. H. Thabet, “Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus,” Clinical Medicine Insights: Endocrinology and Diabetes, vol. 6, pp. 7–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Bolignano, A. Lacquaniti, G. Coppolino et al., “Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients,” Kidney and Blood Pressure Research, vol. 32, no. 2, pp. 91–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. W.-J. Fu, S.-L. Xiong, Y.-G. Fang et al., “Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study,” Endocrine, vol. 41, no. 1, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Zachwieja, J. Soltysiak, P. Fichna et al., “Normal-range albuminuria does not exclude nephropathy in diabetic children,” Pediatric Nephrology, vol. 25, no. 8, pp. 1445–1451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. Al-Refai, S. I. Tayel, A. Ragheb, A. G. Dala, and A. Zahran, “Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria,” Open Journal of Nephrology, vol. 4, no. 1, pp. 37–46, 2014. View at Publisher · View at Google Scholar
  30. V. Garg, M. Kumar, H. S. Mahapatra, A. Chitkara, A. K. Gadpayle, and V. Sekhar, “Novel urinary biomarkers in pre-diabetic nephropathy,” Clinical and Experimental Nephrology, vol. 19, no. 5, pp. 895–900, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Demir, A. Abaci, T. Küme, A. Altincik, G. Çatli, and E. Böber, “Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents,” Journal of Pediatric Endocrinology and Metabolism, vol. 25, no. 5-6, pp. 517–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Ucakturk, B. Avci, G. Genc, O. Ozkaya, and M. Aydin, “Kidney injury molecule-1 and neutrophil gelatinase associated lipocalin in normoalbuminuric diabetic children,” Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 2, pp. 145–151, 2015. View at Publisher · View at Google Scholar
  33. J. Wu, Y. Ding, C. Zhu et al., “Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes,” Experimental and Therapeutic Medicine, vol. 6, no. 6, pp. 1482–1488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. E. Nielsen, H. Reinhard, D. Zdunek et al., “Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 71–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. G. D. Fufaa, E. J. Weil, R. G. Nelson et al., “Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus,” Diabetologia, vol. 58, no. 1, pp. 188–198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. V. Bonventre, “Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3265–3268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, “Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury,” Kidney International, vol. 62, no. 1, pp. 237–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. A. C. Carlsson, M. Calamia, U. Risérus et al., “Kidney injury molecule (KIM)-1 is associated with insulin resistance: results from two community-based studies of elderly individuals,” Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 516–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. N. E. El-Ashmawy, E. A. El-Zamarany, N. F. Khedr, A. I. Abd El-Fattah, and S. A. Eltoukhy, “Kidney injury molecule-1 (Kim-1): an early biomarker for nephropathy in type II diabetic patients,” International Journal of Diabetes in Developing Countries, vol. 35, no. S3, pp. 431–438, 2015. View at Publisher · View at Google Scholar
  40. B. R. Conway, D. Manoharan, D. Manoharan et al., “Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors,” Kidney International, vol. 82, no. 7, pp. 812–818, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. B. K. Tekce, H. Tekce, G. Aktas, and M. Sit, “Evaluation of the urinary kidney injury molecule-1 levels in patients with diabetic nephropathy,” Clinical and Investigative Medicine, vol. 37, no. 6, pp. E377–E383, 2014. View at Google Scholar · View at Scopus
  42. S. A. Ahmed and M. A. Hamed, “Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients,” Journal of Diabetes and Metabolic Disorders, vol. 14, no. 1, article 6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. S. E. Nielsen, K. Rossing, G. Hess et al., “The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: U-NGAL, u-KIM1 and u-LFABP,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 2, pp. 137–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kamijo, T. Sugaya, A. Hikawa et al., “Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules,” American Journal of Pathology, vol. 165, no. 4, pp. 1243–1255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kamijo, T. Sugaya, A. Hikawa et al., “Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease,” Molecular and Cellular Biochemistry, vol. 284, no. 1-2, pp. 175–182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Von Eynatten, M. Baumann, U. Heemann et al., “Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes,” European Journal of Clinical Investigation, vol. 40, no. 2, pp. 95–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide, “Effect of pitavastatin on urinary liver-type fatty acid–binding protein levels in patients with early diabetic nephropathy,” Diabetes Care, vol. 28, no. 11, pp. 2728–2732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. E. Nielsen, T. Sugaya, L. Tarnow et al., “Tubular and glomerular injury in diabetes and the impact of ACE inhibition,” Diabetes Care, vol. 32, no. 9, pp. 1684–1688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Suzuki, T. Babazono, H. Murata, and Y. Iwamoto, “Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy,” Diabetes Care, vol. 28, no. 8, pp. 2038–2039, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Viswanathan, S. Sivakumar, V. Sekar, D. Umapathy, and S. Kumpatla, “Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy,” Indian Journal of Nephrology, vol. 25, no. 5, pp. 269–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. S.-I. Araki, M. Haneda, D. Koya et al., “Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy,” Diabetes Care, vol. 36, no. 5, pp. 1248–1253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. E. Nielsen, T. Sugaya, P. Hovind, T. Baba, H.-H. Parving, and P. Rossing, “Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients,” Diabetes Care, vol. 33, no. 6, pp. 1320–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. N. M. Panduru, C. Forsblom, M. Saraheimo et al., “Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes,” Diabetes Care, vol. 36, no. 7, pp. 2077–2083, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Kamijo-Ikemori, T. Sugaya, T. Yasuda et al., “Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients,” Diabetes Care, vol. 34, no. 3, pp. 691–696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Skálová, “The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment,” Acta Medica, vol. 48, no. 2, pp. 75–80, 2005. View at Google Scholar
  56. S. Uslu, B. Efe, Ö. Alataş et al., “Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients,” Journal of Nephrology, vol. 18, no. 5, pp. 559–567, 2005. View at Google Scholar · View at Scopus
  57. B. R. Bouvet, C. V. Paparella, S. M. M. Arriaga, A. L. Monje, A. M. Amarilla, and A. M. Almará, “Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 58, no. 8, pp. 798–801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. F. P. Udomah, U. E. Ekrikpo, E. Effa, B. Salako, A. Arije, and S. Kadiri, “Association between urinary N-acetyl-beta-D-glucosaminidase and microalbuminuria in diabetic black Africans,” International Journal of Nephrology, vol. 2012, Article ID 235234, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Sheira, N. Noreldin, A. Tamer, and M. Saad, “Urinary biomarker N-acetyl-β-D-glucosaminidase can predict severity of renal damage in diabetic nephropathy,” Journal of Diabetes and Metabolic Disorders, vol. 14, article 4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Mohammadi-Karakani, S. Asgharzadeh-Haghighi, M. Ghazi-Khansari, and R. Hosseini, “Determination of urinary enzymes as a marker of early renal damage in diabetic patients,” Journal of Clinical Laboratory Analysis, vol. 21, no. 6, pp. 413–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Nikolov, M. Boncheva, T. Gruev, S. Biljali, O. Stojceva-Taneva, and E. Masim-Spasovska, “Urinary biomarkers in the early diagnosis of renal damage in diabetes mellitus patients,” Scripta Scientifica Medica, vol. 45, no. 3, pp. 58–64, 2013. View at Publisher · View at Google Scholar
  62. W. K. Gatua, J. N. Makumi, E. M. Njagi, C. S. Kigondu, S. O. Mcligeyo, and S. K. Waithaka, “Evaluation of urinary tubular enzymes as screening markers of renal dysfunction in patients suffering from diabetes mellitus,” Asian Journal of Medical Sciences, vol. 3, no. 3, pp. 84–90, 2011. View at Google Scholar
  63. R. Bansal, D. Lahon, B. B. Thakur, and A. Saikia, “A study of urinary enzymes as a marker of early renal damage in patients suffering from diabetes mellitus,” Indian Journal of Basic & Applied Medical Research, vol. 4, no. 4, pp. 768–776, 2015. View at Google Scholar
  64. V. Ambade, P. Singh, B. L. Somani, and D. Basannar, “Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy,” Indian Journal of Clinical Biochemistry, vol. 21, no. 2, pp. 142–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Vlatković, B. Stojimirović, and R. Obrenović, “Damage of tubule cells in diabetic nephropathy type 2: urinary N-acetyl-β-D-glucosaminidasis and γ-glutamil-transferasis,” Vojnosanitetski Pregled, vol. 64, no. 2, pp. 123–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. V. Vlatković, B. Stojimirović, R. Obrenović, and S. Nogić, “Damage to proximal tubular epithelial cells in type 2 diabetes mellitus,” Medicinski pregled, vol. 60, no. 5-6, pp. 272–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. N. Patel and K. Kalia, “Efficacy of urinary N-acetyl-β-D-glucosaminidase to evaluate early renal tubular damage as a consequence of type 2 diabetes mellitus: a cross-sectional study,” International Journal of Diabetes in Developing Countries, vol. 35, no. 3, supplement, pp. 449–457, 2015. View at Publisher · View at Google Scholar
  68. A. Piwowar, M. Knapik-Kordecka, I. Fus, and M. Warwas, “Urinary activities of cathepsin B, N-acetyl-β-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus,” Medical Science Monitor, vol. 12, no. 5, pp. CR210–CR214, 2006. View at Google Scholar · View at Scopus
  69. E. F. O. Kern, P. Erhard, W. Sun, S. Genuth, and M. F. Weiss, “Early urinary markers of diabetic kidney disease: a nested case-control study from the diabetes Control and Complications Trial (DCCT),” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 824–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. O. Bakoush, A. Grubb, B. Rippe, and J. Tencer, “Urine excretion of protein HC in proteinuric glomerular diseases correlates to urine IgG but not to albuminuria,” Kidney International, vol. 60, no. 5, pp. 1904–1909, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Shore, R. Khurshid, and M. Saleem, “Alpha-1 microglobulin: a marker for early detection of tubular disorders in diabetic nephropathy,” Journal of Ayub Medical College, vol. 22, no. 4, pp. 53–55, 2010. View at Google Scholar · View at Scopus
  72. L. Petrica, A. Vlad, G. Gluhovschi et al., “Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 2, pp. 2516–2525, 2015. View at Google Scholar · View at Scopus
  73. A. Saif and N. Soliman, “Urinary α1-microglobulin and albumin excretion in children and adolescents with type 1 diabetes,” Journal of Diabetes, 2016. View at Publisher · View at Google Scholar
  74. E. Korpinen, A.-M. Teppo, L. Hukkanen, H. K. Åkerblom, C. Grönhagen-Riska, and O. Vaarala, “Urinary transforming growth factor-β1 and α1-microglobulin in children and adolescents with type 1 diabetes,” Diabetes Care, vol. 23, no. 5, pp. 664–668, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. C.-Y. Hong, K. Hughes, K.-S. Chia, V. Ng, and S.-L. Ling, “Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore,” Diabetes Care, vol. 26, no. 2, pp. 338–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Petrica, A. Vlad, G. Gluhovschi et al., “Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study,” PLoS ONE, vol. 9, no. 11, Article ID e112538, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Jain, A. Rajput, Y. Kumar, N. Uppuluri, A. S. Arvind, and U. Tatu, “Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder,” Journal of Association of Physicians of India, vol. 53, pp. 513–520, 2005. View at Google Scholar · View at Scopus
  78. A. Kalansooriya, I. Holbrook, P. Jennings, and P. H. Whiting, “Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes,” British Journal of Biomedical Science, vol. 64, no. 3, pp. 121–123, 2007. View at Google Scholar · View at Scopus
  79. M. L. Robles-Osorio and E. Sabath, “Tubular dysfunction and non-albuminuric renal disease in subjects with type 2 diabetes mellitus,” Revista de Investigacion Clinica, vol. 66, no. 3, pp. 234–239, 2014. View at Google Scholar · View at Scopus
  80. L. Petrica, M. Petrica, A. Vlad et al., “Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study,” Nephron Clinical Practice, vol. 118, no. 2, pp. c155–c164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Petrica, M. Petrica, A. Vlad et al., “Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial,” Wiener Klinische Wochenschrift, vol. 121, no. 23-24, pp. 765–775, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Petrica, A. Vlad, M. Petrica et al., “Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 94, no. 1, pp. 22–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. D. A. Brott, S. T. Furlong, S. H. Adler et al., “Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes,” Drug Design, Development and Therapy, vol. 9, pp. 3191–3198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. X. Zeng, D. Hossain, D. G. Bostwick, G. A. Herrera, B. Ballester, and P. L. Zhang, “Urinary β2-microglobulin is a sensitive indicator for renal tubular injury,” Scholarena Journal (SAJ) of Case Reports, vol. 1, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar
  85. C. Y. Hong, K. S. Chia, and S. L. Ling, “Urine protein excretion among Chinese patients with type 2 diabetes mellitus,” The Medical Journal of Malaysia, vol. 55, no. 2, pp. 220–229, 2000. View at Google Scholar · View at Scopus
  86. N. Aghamohammadzadeh, A. A. Abolfathi, A. Alizadeh, and H. Ghasemi, “Evaluation of microalbuminuria and urine beta 2 microglobulin in patients with type 1 and 2 diabetes,” International Journal of Current Research and Academic Review, vol. 3, no. 6, pp. 451–462, 2015. View at Google Scholar
  87. M. A. Fathy, M. M. Elkady, H. A. Fathy, S. A. Awad, and A. A. Elmenshawy, “Estimation of renal tubular markers for predicting early stage diabetic nephropathy in Egyptian children with type I dibetes mellitus,” Research Journal of Medical Sciences, vol. 4, no. 2, pp. 207–211, 2009. View at Google Scholar
  88. C. Y. Hong, K. S. Chia, and S. L. Ling, “Urinary protein excretion in Type 2 diabetes with complications,” Journal of Diabetes and its Complications, vol. 14, no. 5, pp. 259–265, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Papale, S. Di Paolo, R. Magistroni et al., “Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy,” Diabetes Care, vol. 33, no. 11, pp. 2409–2415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. X. Rao, M. Wan, C. Qiu, and C. Jiang, “Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetes mellitus,” Experimental and Therapeutic Medicine, vol. 8, no. 3, pp. 887–892, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Mise, J. Hoshino, T. Ueno et al., “Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-D-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 593–601, 2016. View at Publisher · View at Google Scholar
  92. H. Dihazi, G. A. Müller, S. Lindner et al., “Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients,” Clinical Chemistry, vol. 53, no. 9, pp. 1636–1645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inukai, “Retinol binding protein-4 levels and clinical features of type 2 diabetes patients,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2712–2719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. E. Novery, S. Susanah, and D. Rachmadi, “The correlation of urine retinol binding protein-4 and serum HbA1c with glomerular filtration rate in type 1 (insulin-dependent) diabetic children: a perspective on the duration of diabetes,” Open Journal of Pediatrics, vol. 5, no. 2, pp. 134–140, 2015. View at Publisher · View at Google Scholar
  95. M. A. K. Salem, S. A. El-Habashy, O. M. Saeid, M. M. K. El-Tawil, and P. H. Tawfik, “Urinary excretion of n-acetyl-β-D-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus,” Pediatric Diabetes, vol. 3, no. 1, pp. 37–41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. A. A. S. Abdallah, K. A. El-Shamy, W. M. Morcos, T. H. Mikhail, and N. N. Fadl, “Early marker for renal impairment and angiopathy in diabetic Egyptian children,” Life Science Journal, vol. 8, no. 3, pp. 358–366, 2011. View at Google Scholar · View at Scopus
  97. N. Zahra, M. A. Javad, and N. Aboalfazl, “Detection of early stage renal disease by elevation of certain low molecular Weight proteins in urine of diabetes patients,” International Journal of Biological Sciences and Applications, vol. 1, no. 1, pp. 15–18, 2014. View at Google Scholar
  98. S. E. Park, N. S. Lee, J. W. Park et al., “Association of urinary RBP4 with insulin resistance, inflammation, and microalbuminuria,” European Journal of Endocrinology, vol. 171, no. 4, pp. 443–449, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. S. M. Titan, J. M. Vieira Jr., W. V. Dominguez et al., “Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy,” Journal of Diabetes and its Complications, vol. 26, no. 6, pp. 546–553, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Catalano, P. H. Winocour, S. Parlongo, I. Gibb, S. Gillespie, and K. G. M. M. Alberti, “Measures of tubular function in normoalbuminuric insulin-dependent diabetic patients and their relationship with sodium lithium countertransport activity,” Nephron, vol. 73, no. 4, pp. 613–618, 1996. View at Publisher · View at Google Scholar · View at Scopus